

Resource Summary Report

Generated by [NIF](#) on Sep 17, 2026

Alberta Cancer Foundation

RRID:SCR_004224

Type: Tool

Proper Citation

Alberta Cancer Foundation (RRID:SCR_004224)

Resource Information

URL: <http://albertacancer.ca/>

Proper Citation: Alberta Cancer Foundation (RRID:SCR_004224)

Description: The Alberta Cancer Foundation is more than a charity. It's a movement for cancer-free lives today, tomorrow and forever. It's a movement of those who know a cancer-free future is possible and who won't settle for some day. It's a movement of those who stand with Albertans who have no choice but to stand up to cancer. It's a movement of those who know something can be done and are willing to do it. For those facing cancer today, in honour of those lost to cancer, and for generations to come, we promise progress. Our mission is to deliver progress in cancer research, prevention, treatment and care by generating community investment for Alberta's coordinated research strategy, the Cross Cancer Institute, Tom Baker Cancer Centre and 15 other cancer centres throughout the province. The Alberta Cancer Foundation is a Registered Charity - Business Number 11878 0477 RR0001. Your dollar fights cancer on every front: research, prevention, screening, early diagnosis, education, treatment and care.

Abbreviations: ACF

Resource Type: institution

Resource Name: Alberta Cancer Foundation

Resource ID: SCR_004224

Alternate IDs: grid.427879.7, nlx_143639, Crossref funder ID: 501100000001

Alternate URLs: <https://ror.org/01k1b2g25>

Record Creation Time: 20220129T080223+0000

Record Last Update: 20260912T195610+0000

Ratings and Alerts

No rating or validation information has been found for Alberta Cancer Foundation.

No alerts have been found for Alberta Cancer Foundation.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Oghinan C, et al. (2026) Risk Factors for Catastrophic Health Events in Head and Neck Cancer: A Scoping Review to Inform Risk Prediction. *Cancers*, 18(12).

Marensi V, et al. (2024) Glutathione transferase P1 is modified by palmitate. *PloS one*, 19(9), e0308500.

Umer BA, et al. (2024) Oncolytic vaccinia virus immunotherapy antagonizes image-guided radiotherapy in mouse mammary tumor models. *PloS one*, 19(3), e0298437.

Amin S, et al. (2019) A strategy for early detection of response to chemotherapy drugs based on treatment-related changes in the metabolome. *PloS one*, 14(4), e0213942.

Jensen KV, et al. (2017) The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model. *PloS one*, 12(12), e0189670.

Bastani M, et al. (2013) A machine learned classifier that uses gene expression data to accurately predict estrogen receptor status. *PloS one*, 8(12), e82144.

Song X, et al. (2013) RasGRPs are targets of the anti-cancer agent ingenol-3-angelate. *PloS one*, 8(8), e72331.

Craddock TJ, et al. (2012) The zinc dyshomeostasis hypothesis of Alzheimer's disease. *PloS one*, 7(3), e33552.

De Wever V, et al. (2012) Isolation of human mitotic protein phosphatase complexes: identification of a complex between protein phosphatase 1 and the RNA helicase Ddx21. *PloS one*, 7(6), e39510.